Over the past 9 days, Extreme Networks, Inc. (NASDAQ: EXTR) stock was observed to have a Historic Volatility of 54.27%. That figure, when expanded to look at the past 100 days, EXTR goes up to 81.63%. In the last 5 days, this stock’s average daily volume is shown as 1,663,160 shares per day, which is higher than the average of 1,900,757 shares per day as measured over the last 100 days. Moving on to look at the price, the movement in the past 5 days was -0.26, while this stock’s price moved +4.70% higher in the past 100 days.
A widely-used method of evaluating a stock’s price at any given moment is looking at it in relation to its 52-week price range. This stock’s recent dip arrives on a trading day that exhibited lower volume than its usual average of 1.76M (measured over the past 3 months). During the trading period, the first transaction completed was recorded at $6.02 per share, the final transaction of the day was recorded at 6.53. At the moment, this stock’s 52-week high is $15.55 and its 52-week low is $4.81.
This publicly-traded organization managed to generate a trailing 12-month revenue of 1.01B. Bearing that in mind, this company is experiencing top-line progress, as its year-over-year quarterly revenue has grown by 13.30%. This company’s current market capitalization is 700.43M.
Recently, Extreme Networks, Inc. (NASDAQ: EXTR) has caught the attention – and in-depth analysis – of numerous Wall Street analysts. Similarly, in a research note sent out on February 7th, 2018 from Needham, analysts Reiterated the shares of this stock to Buy and set a price target at $15.50.Additionally, in a research note made public on February 7th, 2018, Analysts at DA Davidson Reiterated common shares of EXTR stock to Buy – combined with a 12-month price target of $17.
Is Akebia Therapeutics, Inc. a good investment? Let’s take a look at what leading Wall Street experts have to say about this particular stock. For shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA), there are currently ratings available from 6 different stock market analysts who have all given their professional opinions. On average, these analysts currently have a Moderate Buy recommendation with a mean rating of 4.33. This is in comparison to the average recommendation from a month ago, which was a Strong Buy with an average rating of 4.43. Similarly, the average rating observed 2 months ago was a Strong Buy with the mean numerical rating of 4.43, and the average rating observed 3 months ago was a Strong Buy with a mean numerical rating of 4.43.
But what do Wall Street experts have to say about how this company is performing behind the scenes? Looking at its overall profits, Akebia Therapeutics, Inc. reported earnings of -0.46 for the quarter ending Sep-18. This compares to the average analyst prediction of -0.64, representing a difference of 0.18, and therefore a surprise factor of -28.28. For the financial results of the preceding quarter, the company posted earnings of -0.60, in comparison to the average analyst forecast of -0.51 – representing a difference of -0.09 and a surprise factor of -18.32.
Continuing discussion of current price performance, Akebia Therapeutics, Inc. has a total market value of 472.91M at the time of writing – representing $56.84M outstanding shares. Turning to other widely-considered trading data, this company’s half yearly performance is observed to be negative at -17.71%. The Average True Range for this company’s stock is currently 0.63, and its current Beta is sitting at 1.10.
Now let’s take a look at what’s on the horizon: for the financial results of the current quarter, So far – there have been 2 different Wall Street analysts that have provided investors with their professional projections for Akebia Therapeutics, Inc. For net profit, these analysts are collectively forecasting an average estimate of -$0.80 per share, versus the $0.25 per share reported in the year-ago quarter. The lowest earnings per share prediction was -$0.98 per share, with the highest forecast pointing toward -$0.98 per share. Compared to the year-ago period, experts are projecting a growth rate of -420.00%.